Wolf J - Search Results

1

Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.

Brennan FR, Andrews L, Arulanandam AR, Blumel J, Fikes J, Grimaldi C, Lansita J, Loberg LI, MacLachlan T, Milton M, Parker S, Tibbitts J, Wolf J, Allamneni KP. Brennan FR, et al. Among authors: wolf j. Regul Toxicol Pharmacol. 2018 Oct;98:98-107. doi: 10.1016/j.yrtph.2018.07.009. Epub 2018 Jul 17. Regul Toxicol Pharmacol. 2018. PMID: 30026135

2

Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates.

Santostefano M, Herzyk D, Montgomery D, Wolf J. Santostefano M, et al. Among authors: wolf j. Regul Toxicol Pharmacol. 2019 Nov;108:104476. doi: 10.1016/j.yrtph.2019.104476. Epub 2019 Sep 16. Regul Toxicol Pharmacol. 2019. PMID: 31536773

3

Nonclinical safety assessment of vaccines and adjuvants.

Wolf JJ, Kaplanski CV, Lebron JA. Wolf JJ, et al. Methods Mol Biol. 2010;626:29-40. doi: 10.1007/978-1-60761-585-9_3. Methods Mol Biol. 2010. PMID: 20099119 Review.

4

An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.

Poulet FM, Wolf JJ, Herzyk DJ, DeGeorge JJ. Poulet FM, et al. Among authors: wolf jj. Birth Defects Res B Dev Reprod Toxicol. 2016 Apr;107(2):108-19. doi: 10.1002/bdrb.21176. Epub 2016 Apr 7. Birth Defects Res B Dev Reprod Toxicol. 2016. PMID: 27062127 Review.

5

Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists.

Sellers RS, Nelson K, Bennet B, Wolf J, Tripathi N, Chamanza R, Perron Lepage MF, Adkins K, Laurent S, Troth SP. Sellers RS, et al. Among authors: wolf j. Toxicol Pathol. 2020 Feb;48(2):257-276. doi: 10.1177/0192623319875085. Epub 2019 Oct 8. Toxicol Pathol. 2020. PMID: 31594486

6

Ensuring the quality, potency and safety of vaccines during preclinical development.

Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ. Lebron JA, et al. Among authors: wolf jj. Expert Rev Vaccines. 2005 Dec;4(6):855-66. doi: 10.1586/14760584.4.6.855. Expert Rev Vaccines. 2005. PMID: 16372881 Free article. Review.

7

Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens.

Wolf J, Bruno S, Eichberg M, Jannat R, Rudo S, VanRheenen S, Coller BA. Wolf J, et al. NPJ Vaccines. 2020 Jun 15;5(1):51. doi: 10.1038/s41541-020-0204-7. eCollection 2020. NPJ Vaccines. 2020. PMID: 32566261 Free PMC article. Review.

8

The impact of export regulations on recombinant viral vaccine development for emerging infectious diseases.

Wolf J, Hansen R, Hassis K, Lapps W, Warmuth E. Wolf J, et al. Vaccine. 2020 Oct 27;38(46):7198-7200. doi: 10.1016/j.vaccine.2020.09.057. Epub 2020 Oct 5. Vaccine. 2020. PMID: 33032845 Free PMC article. No abstract available.

9

[No title available]

[No authors listed] [No authors listed] PMID: 33580080

10

Evaluation of a 9-valent HPV vaccine in Sprague-Dawley rats: Nonclinical studies assessing general, reproductive, and developmental toxicity.

Wise LD, Wolf JJ, Plitnick LM. Wise LD, et al. Among authors: wolf jj. Vaccine. 2018 Oct 15;36(43):6401-6407. doi: 10.1016/j.vaccine.2018.08.071. Epub 2018 Sep 17. Vaccine. 2018. PMID: 30236634

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,525 results

Search Page

Filters